Neurogene (NGNE) Net Income towards Common Stockholders (2013 - 2026)
Neurogene (NGNE) posted Net Income towards Common Stockholders of -$38.3 million for Q1 2026, down 54.03% on a QoQ basis from -$24.9 million in Q4 2025, and down 63.53% year-over-year from -$105.0 million in Q1 2025.
Neurogene (NGNE) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Neurogene's Net Income towards Common Stockholders history runs 14 years deep, the most recent figure standing at -$38.3 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 63.53% year-over-year to -$38.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$111.8 million (up 5.66% YoY) and the FY2025 annual result came in at -$231.6 million, down 22.45% from the prior year.
- Net Income towards Common Stockholders was -$38.3 million for Q1 2026 at Neurogene, down from -$24.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$11.9 million in Q2 2023 and bottomed at -$49.8 million in Q4 2022.
- A 5-year average of -$25.1 million and a median of -$23.4 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders soared 72.34% — and 2024, when it tumbled 296.86%.
- Neurogene's Net Income towards Common Stockholders stood at -$49.8 million in 2022, then soared by 72.0% to -$14.0 million in 2023, then tumbled by 65.63% to -$23.1 million in 2024, then declined by 7.55% to -$24.9 million in 2025, then sank by 54.03% to -$38.3 million in 2026.
- Business Quant data shows NGNE's Net Income towards Common Stockholders at -$38.3 million in Q1 2026, -$24.9 million in Q4 2025, and -$24.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Neurogene | 776.69 Mn | 776.69 Mn | - | -38.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.29 Mn |
| Dec 31, 2025 | -24.86 Mn |
| Sep 30, 2025 | -23.96 Mn |
| Jun 30, 2025 | -24.65 Mn |
| Mar 31, 2025 | -23.41 Mn |
| Dec 31, 2024 | -23.11 Mn |
| Sep 30, 2024 | -40.34 Mn |
| Jun 30, 2024 | -31.60 Mn |
| Mar 31, 2024 | -48.66 Mn |
| Dec 31, 2023 | -13.96 Mn |
| Sep 30, 2023 | -14.57 Mn |
| Jun 30, 2023 | -11.87 Mn |
| Mar 31, 2023 | -12.26 Mn |
| Dec 31, 2022 | -49.84 Mn |
| Sep 30, 2022 | -13.70 Mn |
| Jun 30, 2022 | -15.94 Mn |
| Mar 31, 2022 | -15.39 Mn |
| Dec 31, 2021 | -40.37 Mn |
| Sep 30, 2021 | -33.83 Mn |
| Jun 30, 2021 | -41.41 Mn |